CytomX Therapeutics, Inc. (CTMX): Price and Financial Metrics
CTMX Price/Volume Stats
|Current price||$1.37||52-week high||$3.02|
|Prev. close||$1.33||52-week low||$1.04|
|Day high||$1.43||Avg. volume||934,010|
|50-day MA||$1.26||Dividend yield||N/A|
|200-day MA||$1.60||Market Cap||91.81M|
CTMX Stock Price Chart Interactive Chart >
CTMX POWR Grades
- Growth is the dimension where CTMX ranks best; there it ranks ahead of 95.93% of US stocks.
- The strongest trend for CTMX is in Quality, which has been heading down over the past 177 days.
- CTMX's current lowest rank is in the Momentum metric (where it is better than 4.01% of US stocks).
CTMX Stock Summary
- CYTOMX THERAPEUTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 4.88% of US listed stocks.
- CTMX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 4.3% of US stocks.
- With a year-over-year growth in debt of -29.61%, CYTOMX THERAPEUTICS INC's debt growth rate surpasses only 11.25% of about US stocks.
- Stocks that are quantitatively similar to CTMX, based on their financial statements, market capitalization, and price volatility, are CRDF, HYLN, DBVT, VTGN, and PULM.
- Visit CTMX's SEC page to see the company's official filings. To visit the company's web site, go to www.cytomx.com.
CTMX Valuation Summary
- CTMX's EV/EBIT ratio is -0.7; this is 107.11% lower than that of the median Healthcare stock.
- Over the past 98 months, CTMX's price/sales ratio has gone down 60.
Below are key valuation metrics over time for CTMX.
CTMX Growth Metrics
- The 3 year cash and equivalents growth rate now stands at -14.07%.
- Its 3 year revenue growth rate is now at -5.43%.
- The 3 year net cashflow from operations growth rate now stands at -30.48%.
The table below shows CTMX's growth in key financial areas (numbers in millions of US dollars).
|Date||Revenue||Operating Cash Flow||Net Income to Common Stock|
CTMX's Quality FactorsThe “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
- CTMX has a Quality Grade of D, ranking ahead of 22.16% of graded US stocks.
- CTMX's asset turnover comes in at 0.169 -- ranking 210th of 682 Pharmaceutical Products stocks.
- JNJ, LEXX, and ORGS are the stocks whose asset turnover ratios are most correlated with CTMX.
The table below shows CTMX's key quality metrics over time.
|Period||Asset Turnover||Gross Margin||ROIC|
CytomX Therapeutics, Inc. (CTMX) Company Bio
CytomX Therapeutics develops a novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology. The company was founded in 2008 and is based in San Francisco, California.
CTMX Latest News Stream
|Loading, please wait...|
CTMX Latest Social Stream
View Full CTMX Social Stream
Latest CTMX News From Around the Web
Below are the latest news stories about CYTOMX THERAPEUTICS INC that investors may wish to consider to help them evaluate CTMX as an investment opportunity.
Freeline Therapeutics (FRLN) is set to be acquired by Syncona Ltd. The transaction is expected to be closed in the first quarter of 2024. Shares rise.
The FDA clears Immix's (IMMX) investigational new drug application for BCMA CAR-T cell therapy, NXC-201, to expand clinical studies in relapsed/refractory AL amyloidosis to the United States. Stock falls.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Good day and thank you for standing by. Welcome to the CytomX Therapeutics Third Quarter 2023 Financial Results. At this time, all participants are in a listen only-mode. After the speaker’s presentation there will be a question and answer session. [Operator Instructions] […]
CTMX Price Returns
Continue Researching CTMXWant to do more research on CytomX Therapeutics Inc's stock and its price? Try the links below:
CytomX Therapeutics Inc (CTMX) Stock Price | Nasdaq
CytomX Therapeutics Inc (CTMX) Stock Quote, History and News - Yahoo Finance
CytomX Therapeutics Inc (CTMX) Stock Price and Basic Information | MarketWatch